{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:56:50Z","timestamp":1792173410412,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11596-020-2253-6","type":"journal-article","created":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T04:11:46Z","timestamp":1601179906000},"page":"851-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Recent Developments in the Treatment of Wet Age-related Macular Degeneration"],"prefix":"10.1007","volume":"40","author":[{"given":"Zois","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"1","key":"2253_CR1","doi-asserted-by":"publisher","first-page":"a017178","DOI":"10.1101\/cshperspect.a017178","volume":"5","author":"Y Yonekawa","year":"2015","unstructured":"Yonekawa Y, Kim IK. Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med, 2015,5(1):a017178","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Suppl.1","key":"2253_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000337154","volume":"227","author":"D Veritti","year":"2012","unstructured":"Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica, 2012,227 (Suppl. 1):11\u201320","journal-title":"Ophthalmologica"},{"key":"2253_CR3","unstructured":"Yanoff M, Duker JS. Age-Related Macular Degeneration. Ophthalmology 4th edition. Elsevier Saunders. 2014:580\u2013604."},{"key":"2253_CR4","doi-asserted-by":"crossref","unstructured":"Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 7th edition. Elsevier Health Sciences. 2011:594\u2013646.","DOI":"10.1016\/B978-0-7020-4093-1.00014-8"},{"key":"2253_CR5","doi-asserted-by":"crossref","unstructured":"Denniston A, Murray P, editors. Medical Retina. Oxford handbook of ophthalmology. OUP Oxford. 2014:515\u2013592.","DOI":"10.1093\/med\/9780199679980.003.0013"},{"key":"2253_CR6","unstructured":"Gerhard K. Lang. Retina. Ophthalmology: A Pocket Textbook Atlas. Thieme. 2007:305\u2013372."},{"key":"2253_CR7","unstructured":"Kanski JJ, Bowling B. Acquired Macular Disorders. Synopsis of Clinical Ophthalmology 3rd edition. Elsevier Health Sciences. 2013:268\u2013287."},{"issue":"10","key":"2253_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40266-015-0300-y","volume":"32","author":"A Garc\u00eda-Layana","year":"2015","unstructured":"Garc\u00eda-Layana A, Figueroa MS, Araiz J, et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging, 2015,32(10):797\u2013807","journal-title":"Drugs Aging"},{"key":"2253_CR9","unstructured":"Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 8th edition. Elsevier Health Sciences. 2016:580\u2013639."},{"key":"2253_CR10","doi-asserted-by":"crossref","unstructured":"Coscas G. Optical coherence tomography in age-related macular degeneration. Springer Science & Business Media. 2009 Jul 25.","DOI":"10.1007\/978-3-642-01467-3"},{"key":"2253_CR11","doi-asserted-by":"publisher","first-page":"117917211668607","DOI":"10.1177\/1179172116686075","volume":"9","author":"J Ma","year":"2017","unstructured":"Ma J, Desai R, Nesper P, et al.. Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration. Ophthalmol Eye Dis, 2017,9:1179172116686075","journal-title":"Ophthalmol Eye Dis"},{"issue":"2","key":"2253_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/OPX.0000000000000997","volume":"94","author":"A Ly","year":"2017","unstructured":"Ly A, Nivison-Smith L, Assaad N, et al. Fundus autofluorescence in age-related macular degeneration. Optometry Vis Sci, 2017,94(2):246","journal-title":"Optometry Vis Sci"},{"issue":"4","key":"2253_CR13","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.4238\/2013.December.2.11","volume":"12","author":"Q Peng","year":"2013","unstructured":"Peng Q, Dong Y, Zhao PQ. Fundus autofluorescence in exudative age-related macular degeneration. Genet Mol Res, 2013,12(4):6140\u20136148","journal-title":"Genet Mol Res"},{"key":"2253_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000438969","volume":"55","author":"J Shao","year":"2016","unstructured":"Shao J, Choudhary MM, Schachat AP.. Neovascular age-related macular degeneration. Dev Ophthalmol, 2016,55:125\u2013136","journal-title":"Dev Ophthalmol"},{"key":"2253_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CIA.S143508","volume":"12","author":"WM Al-Zamil","year":"2017","unstructured":"Al-Zamil WM, Yassin SA.. Recent developments in age-related macular degeneration: a review. Clin Interv Aging, 2017,12:1313","journal-title":"Clin Interv Aging"},{"key":"2253_CR16","doi-asserted-by":"crossref","unstructured":"Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ). 2011,5:57","DOI":"10.2147\/OPTH.S16444"},{"issue":"9","key":"2253_CR17","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.ophtha.2013.02.016","volume":"120","author":"TL Jackson","year":"2013","unstructured":"Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology, 2013,120(9):1893\u20131900","journal-title":"Ophthalmology"},{"key":"2253_CR18","first-page":"1829","volume":"9","author":"JE Neffendorf","year":"2015","unstructured":"Neffendorf JE, Jackson TL.. Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. Clin Ophthalmol (Auckland, NZ), 2015,9:1829","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"3","key":"2253_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5114\/ceji.2016.63132","volume":"41","author":"D Po\u017carowska","year":"2016","unstructured":"Po\u017carowska D, Po\u017carowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol, 2016,41(3):311","journal-title":"Cent Eur J Immunol"},{"issue":"5","key":"2253_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1517\/14712598.2016.1167182","volume":"16","author":"M Hassan","year":"2016","unstructured":"Hassan M, Afridi R, Sadiq MA, et al. The role of Aflibercept in the management of age-related macular degeneration. Expert Opin Biol Ther, 2016,16(5):699\u2013709","journal-title":"Expert Opin Biol Ther"},{"key":"2253_CR21","first-page":"5397","volume":"9","author":"J Ba","year":"2015","unstructured":"Ba J, Peng RS, Xu D, et al.. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Dev Ther, 2015,9:5397\u20139405","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"2253_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/14656566.2012.658368","volume":"13","author":"M Ohr","year":"2012","unstructured":"Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother, 2012,13(4):585\u2013591","journal-title":"Expert Opin Pharmacother"},{"key":"2253_CR23","first-page":"2355","volume":"9","author":"C Balaratnasingam","year":"2015","unstructured":"Balaratnasingam C, Dhrami-Gavazi E, McCann JT, et al.. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol (Auckland, NZ), 2015,9:2355","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"4","key":"2253_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1120672119832432","volume":"29","author":"Z Papadopoulos","year":"2019","unstructured":"Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol, 2019,29(4):368\u2013378","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"2253_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40266-012-0015-2","volume":"29","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Aflibercept for intravitreal injection. Drugs Aging, 2012,29(10):839\u2013846","journal-title":"Drugs Aging"},{"issue":"7","key":"2253_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye, 2013,27(7):787\u2013794","journal-title":"Eye"},{"issue":"10","key":"2253_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1517\/14712598.2012.707176","volume":"12","author":"C Costagliola","year":"2012","unstructured":"Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther, 2012,12(10):1299\u20131313","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2253_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","volume":"159","author":"N Rayess","year":"2015","unstructured":"Rayess N, Houston III SS, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol, 2015,159(1):3\u20138","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2253_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","volume":"100","author":"D Chin-Yee","year":"2016","unstructured":"Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol, 2016,100(7):914\u2013917","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"2253_CR30","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology, 2015,122(12):2514\u20132522","journal-title":"Ophthalmology"},{"issue":"4","key":"2253_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina, 2017,1(4):314\u2013321","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"2253_CR32","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","volume":"257","author":"M Augsburger","year":"2019","unstructured":"Augsburger M, Sarra GM, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol Graefes Arch Clin Exp Ophthalmol, 2019,257(9):1889\u20131895","journal-title":"Graefes Arch Clin Exp Ophthalmol Graefes Arch Clin Exp Ophthalmol"},{"issue":"10Suppl","key":"2253_CR33","first-page":"S172","volume":"25","author":"NM Holekamp","year":"2019","unstructured":"Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Managed Care, 2019,25(10 Suppl):S172\u2013181","journal-title":"Am J Managed Care"},{"key":"2253_CR34","first-page":"1","volume":"30","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kumar N, Kuppermann BD, et al.. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye, 2019,30:1\u20135","journal-title":"Eye"},{"key":"2253_CR35","first-page":"2311","volume":"9","author":"X Lu","year":"2015","unstructured":"Lu X, Sun X.. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des, Dev Ther, 2015,9:2311\u20132320","journal-title":"Drug Des, Dev Ther"},{"issue":"9","key":"2253_CR36","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology, 2014,121(9):1740\u20131747","journal-title":"Ophthalmology"},{"issue":"1","key":"2253_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2019","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 2019,127(1):72\u201384","journal-title":"Ophthalmology"},{"issue":"18","key":"2253_CR38","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Brolucizumab: First Approval. Drugs, 2019,79(18):1997\u20132000","journal-title":"Drugs"},{"key":"2253_CR39","unstructured":"Boxler D. Brolucizumab-dbll Approved by FDA for Wet AMD."},{"key":"2253_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/OPTH.S184706","volume":"13","author":"NA Yannuzzi","year":"2019","unstructured":"Yannuzzi NA, Freund KB. Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ) 2019,13:1323\u20131329","journal-title":"Clin Ophthalmol (Auckland, NZ)"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-020-2253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-020-2253-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-020-2253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T08:15:03Z","timestamp":1604045703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-020-2253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s11596-020-2253-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}